IBA develops Streptamer technology:
This article was originally published in Clinica
German biotech company IBA has developed jointly with the Technical University in Munich, a Streptamer technology - a novel method to functionally isolate and characterise antigen-specific T-cells. Streptamers enable, for the first time, a reversible, antigen-specific staining of T-cells leaving the isolated T-cells phenotypically and functionally indistinguishable from untreated cells, says the Gottingen company. "We believe that our Streptamer technology will have a significant impact on immunological research and the development of T-cell-based therapeutics and diagnostics," said Dr Lothar Germeroth, IBA's CEO.